Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...
In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...
Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...
Flu vaccines that take a page from the COVID-19 vaccine platform are making progress in clinical trials. In a phase 3 trial, Pfizer’s mRNA flu vaccine outperformed a traditional vaccine, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback